1475 related articles for article (PubMed ID: 23975517)
1. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.
Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y
Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517
[TBL] [Abstract][Full Text] [Related]
2. Cognitive correlates of α4β2 nicotinic acetylcholine receptors in mild Alzheimer's dementia.
Sabri O; Meyer PM; Gräf S; Hesse S; Wilke S; Becker GA; Rullmann M; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Tiepolt S; Fischer S; Deuther-Conrad W; Hegerl U; Barthel H; Schönknecht P; Brust P
Brain; 2018 Jun; 141(6):1840-1854. PubMed ID: 29672680
[TBL] [Abstract][Full Text] [Related]
3. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
[TBL] [Abstract][Full Text] [Related]
4. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
5. In vivo Depiction of α7 Nicotinic Receptor Loss for Cognitive Decline in Alzheimer's Disease.
Nakaizumi K; Ouchi Y; Terada T; Yoshikawa E; Kakimoto A; Isobe T; Bunai T; Yokokura M; Suzuki K; Magata Y
J Alzheimers Dis; 2018; 61(4):1355-1365. PubMed ID: 29376856
[TBL] [Abstract][Full Text] [Related]
6. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
7. Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer's Disease.
Oboshi Y; Kikuchi M; Terada T; Yoshikawa E; Bunai T; Ouchi Y
J Alzheimers Dis; 2016 May; 53(3):817-30. PubMed ID: 27258412
[TBL] [Abstract][Full Text] [Related]
8. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.
Rabinovici GD; Furst AJ; Alkalay A; Racine CA; O'Neil JP; Janabi M; Baker SL; Agarwal N; Bonasera SJ; Mormino EC; Weiner MW; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ
Brain; 2010 Feb; 133(Pt 2):512-28. PubMed ID: 20080878
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
10. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
[TBL] [Abstract][Full Text] [Related]
11. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.
Sabri O; Becker GA; Meyer PM; Hesse S; Wilke S; Graef S; Patt M; Luthardt J; Wagenknecht G; Hoepping A; Smits R; Franke A; Sattler B; Habermann B; Neuhaus P; Fischer S; Tiepolt S; Deuther-Conrad W; Barthel H; Schönknecht P; Brust P
Neuroimage; 2015 Sep; 118():199-208. PubMed ID: 26037057
[TBL] [Abstract][Full Text] [Related]
12. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
Frings L; Hellwig S; Spehl TS; Bormann T; Buchert R; Vach W; Minkova L; Heimbach B; Klöppel S; Meyer PT
Brain; 2015 Oct; 138(Pt 10):3089-99. PubMed ID: 26280595
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
15. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
Kreisl WC; Lyoo CH; McGwier M; Snow J; Jenko KJ; Kimura N; Corona W; Morse CL; Zoghbi SS; Pike VW; McMahon FJ; Turner RS; Innis RB;
Brain; 2013 Jul; 136(Pt 7):2228-38. PubMed ID: 23775979
[TBL] [Abstract][Full Text] [Related]
16. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment.
Tosun D; Schuff N; Mathis CA; Jagust W; Weiner MW;
Brain; 2011 Apr; 134(Pt 4):1077-88. PubMed ID: 21429865
[TBL] [Abstract][Full Text] [Related]
17. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
18. Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease.
Meyer PM; Tiepolt S; Barthel H; Hesse S; Sabri O
Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):376-86. PubMed ID: 25387119
[TBL] [Abstract][Full Text] [Related]
19. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation.
Villeneuve S; Rabinovici GD; Cohn-Sheehy BI; Madison C; Ayakta N; Ghosh PM; La Joie R; Arthur-Bentil SK; Vogel JW; Marks SM; Lehmann M; Rosen HJ; Reed B; Olichney J; Boxer AL; Miller BL; Borys E; Jin LW; Huang EJ; Grinberg LT; DeCarli C; Seeley WW; Jagust W
Brain; 2015 Jul; 138(Pt 7):2020-33. PubMed ID: 25953778
[TBL] [Abstract][Full Text] [Related]
20. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
